| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 62778-0071-01 | 62778-0071 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 23, 2009 | Dec 23, 2009 | No Longer Used | |
| 00088-1202-05 | 00088-1202 | Dolasetron mesylate | Anzemet | 50.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 11, 1997 | Jun 30, 2017 | No Longer Used |
| 63187-0636-15 | 63187-0636 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 2, 2016 | In Use | |
| 55513-0054-01 | 55513-0054 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct 1, 2001 | Dec 31, 2008 | No Longer Used | |||
| 55513-0004-04 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
| 16729-0240-03 | 16729-0240 | FOSAPREPITANT | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Oct 22, 2020 | In Use | |
| 00069-0291-10 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
| 00378-0315-01 | 00378-0315 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 82650-0144-01 | 82650-0144 | PALONOSETRON HYDROCHLORIDE | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Mar 23, 2018 | In Use | |
| 62856-0797-01 | 62856-0797 | Palonosetron hydrochloride | Aloxi | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 28, 2014 | Oct 31, 2022 | No Longer Used |
| 42806-0133-21 | 42806-0133 | Leucovorin Calcium | Leucovorin Calcium | 10.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jan 1, 2021 | In Use | |
| 68001-0648-36 | 68001-0648 | Leucovorin Calcium | Leucovorin Calcium | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | May 10, 2025 | In Use | |
| 55700-0631-30 | 55700-0631 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 25, 2018 | Jan 31, 2028 | In Use |
| 00781-3415-95 | 00781-3415 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct 1, 2024 | In Use | |
| 68788-9402-06 | 68788-9402 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 23, 2017 | In Use | |
| 64380-0127-02 | 64380-0127 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Aug 16, 2022 | In Use | |
| 43063-0770-06 | 43063-0770 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 3, 2014 | In Use | |
| 30698-0120-05 | 30698-0120 | Dolasetron mesylate | Anzemet | 50.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 11, 1997 | May 24, 2021 | In Use |
| 58118-7500-08 | 58118-7500 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 13, 2018 | In Use | |
| 59676-0302-02 | 59676-0302 | Erythropoietin | Procrit | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 1, 1989 | Jan 8, 2014 | In Use | |
| 51079-0520-56 | 51079-0520 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 26, 2009 | Jul 31, 2015 | No Longer Used |
| 68071-1547-01 | 68071-1547 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 26, 2017 | Dec 31, 2019 | In Use |
| 55150-0266-05 | 55150-0266 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Sep 26, 2016 | In Use | ||
| 55513-0148-20 | 55513-0148 | Epoetin alfa | Epogen | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Apr 14, 2025 | In Use | ||
| 00378-7732-05 | 00378-7732 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Oct 9, 2014 | No Longer Used |
Found 11765 results — Export these results
Home